Breast cancer is a heterogeneous disease with multiple histological, biological, and molecular subtypes. Several fundamental studies have highlighted the activation of specific metabolic pathways in aggressive breast cancers. The aim of this thesis was to identify a signature or markers of the metabolome in localized breast cancer at high risk...
-
July 7, 2023 (v1)PublicationUploaded on: October 15, 2023
-
October 25, 2019 (v1)Publication
The purpose of this study was to develop an algorithm to assist oncologists validate chemotherapy for early-stage breast cancer in elderly patients.Patients over 70 with early-stage breast cancer and a standardised Comprehensive Geriatric Assessment (CGA) made at baseline were screened. We assessed the benefit/risk balance of a therapeutic...
Uploaded on: December 4, 2022 -
December 2021 (v1)Journal article
Metastatic breast cancer is the second most common cause of brain metastasis (BM), and this problem is particularly marked for the amplified HER2 subtype (HER2+), with a cumulative incidence reaching up to 49 % in the ER–/HER2+ subgroup. Literature review shows that therapeutic progress has been major since the marketing of systemic anti-HER2+...
Uploaded on: October 1, 2024 -
December 2021 (v1)Journal article
Abstract Background Supervised classification methods have been used for many years for feature selection in metabolomics and other omics studies. We developed a novel primal-dual based classification method (PD-CR) that can perform classification with rejection and feature selection on high dimensional datasets. PD-CR projects data onto a low...
Uploaded on: February 22, 2023 -
December 15, 2021 (v1)Journal article
Abstract Background Supervised classification methods have been used for many years for feature selection in metabolomics and other omics studies. We developed a novel primal-dual based classification method (PD-CR) that can perform classification with rejection and feature selection on high dimensional datasets. PD-CR projects data onto a low...
Uploaded on: December 3, 2022 -
December 2021 (v1)Journal article
Abstract Background Supervised classification methods have been used for many years for feature selection in metabolomics and other omics studies. We developed a novel primal-dual based classification method (PD-CR) that can perform classification with rejection and feature selection on high dimensional datasets. PD-CR projects data onto a low...
Uploaded on: December 4, 2022 -
2023 (v1)Journal article
International audience
Uploaded on: January 13, 2025 -
April 2023 (v1)Journal article
Purpose: Identification of metabolomic biomarkers of high SBR grade in non-metastatic breast cancer. Methods: This retrospective bicentric metabolomic analysis included a training set (n = 51) and a validation set (n = 49) of breast cancer tumors, all classified as high-grade (grade III) or low-grade (grade I–II). Metabolomes of tissue samples...
Uploaded on: October 13, 2023 -
July 23, 2020 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
March 1, 2019 (v1)Journal article
International audience
Uploaded on: October 23, 2024 -
June 2018 (v1)Journal article
Breast cancer (BC) metastatic behavior varies according to the hormone receptors (HR) and HER2 statuses. Indeed, patients with triple-negative (TN) and HER2+ tumors are at higher risk of brain metastases (BM). The objective of this multinational cohort was to evaluate BM kinetics depending on the BC subtype. We retrospectively analyzed a series...
Uploaded on: December 4, 2022 -
February 2018 (v1)Journal article
BACKGROUND:Several prognostic scores have been developed to estimate survival of breast cancer (BC) patients with brain metastases (BM). Modified Breast Graded Prognostic Assessment (GPA), based on a single-institution cohort of 1552 patients, has been proposed as refinement of Breast-GPA. In addition to age, tumour subtype and KPS, Modified...
Uploaded on: December 4, 2022 -
September 14, 2018 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
May 20, 2021 (v1)Journal article
1064 Background: In 11.2018, the PIK3CA-inhibitor alpelisib was made available in France through an early access program (EAP), in combination with fulvestrant in pre-treated PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer (ABC) patients. Patients had to received two or more prior systemic treatments for ABC, including an...
Uploaded on: December 3, 2022